Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Bausch + Lomb (NYSE/TSX: BLCO) reported Q2 2026 revenue of $1.394B, up 9% year over year (8% constant currency). GAAP net loss was $14M versus $62M a year earlier. Adjusted EBITDA was $241M. The company raised full-year 2026 revenue and adjusted EBITDA guidance and cited growth in Surgical and Pharmaceuticals.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of Q2 outperformance (revenue growth, operating income improvement, higher adjusted EBITDA) and an explicit raise to full-year 2026 non-GAAP guidance, which can shift consensus estimates and valuation multiples.
Market read
Q2 results show broad-based growth across Vision Care, Surgical, and Pharmaceuticals, and the company raised full-year 2026 guidance, increasing the probability of upward estimate revisions.
What to watch
The release emphasizes non-GAAP metrics and constant-currency growth; FX sensitivity and the lack of GAAP reconciliation for forward guidance could temper conviction.
Background
Bausch + Lomb is executing a three-year growth plan outlined at Investor Day in November, with this quarter showing broad-based segment growth and cash-flow improvement.
Ticker impact
Bausch + Lomb reported Q2 2026 revenue of $1.394B (+9% YoY) and raised full-year 2026 revenue and adjusted EBITDA guidance.
Likely positive near-term reaction as guidance raise and margin/cash-flow improvement reduce downside risk.
The article is a primary earnings release with quantified results (revenue, adjusted EBITDA, operating income, operating cash flow) and an explicit full-year guidance increase.
Market effects
Eye-care and specialty pharma peers may see read-across demand for contact lenses, dry eye, and branded ophthalmic drugs if BLCO’s growth is sustained.
Limited direct regional spillover; results are global but could influence North American healthcare sentiment.
Moderate global relevance via international pharmaceuticals growth and constant-currency outperformance.
Counterpoint
Despite GAAP net loss, investors may focus on sustainability of premium IOL mix and whether cash-flow strength persists beyond the quarter.
Key entities
- companyBausch + Lomb Corporation
Eye-health company reporting Q2 2026 results and raising full-year 2026 revenue and adjusted EBITDA guidance.
- product_pipelineenVista Beyond
Investigational IOL with topline results from a pivotal clinical study reported alongside the earnings release.
- productMIEBO
Branded ophthalmic therapy cited as driving branded pharmaceuticals growth.
- productXIIdra
Branded ophthalmic therapy cited as driving branded pharmaceuticals growth.
